Stockscreener 앱 받기
52.57
0.53%
-0.282
전일 마감가:
$52.85
열려 있는:
$52.56
하루 거래량:
550.06K
Relative Volume:
0.23
시가총액:
$10.11B
수익:
$2.95B
순이익/손실:
$523.88M
주가수익비율:
19.54
EPS:
2.69
순현금흐름:
$620.18M
1주 성능:
-1.72%
1개월 성능:
-5.16%
6개월 성능:
-15.25%
1년 성능:
-20.36%
1일 변동 폭
$51.80
$52.66
1주일 범위
$51.00
$54.75
52주 변동 폭
$51.00
$73.51
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
BMRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
52.66 | 10.15B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.82 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.03 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
427.46 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
842.63 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.93 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
바이오마린 Stock (BMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-08 | 개시 | H.C. Wainwright | Neutral |
| 2025-09-03 | 개시 | Raymond James | Outperform |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-02-24 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 개시 | Evercore ISI | Outperform |
| 2023-11-15 | 개시 | Wells Fargo | Overweight |
| 2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 개시 | Raymond James | Mkt Perform |
| 2023-09-18 | 개시 | UBS | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 개시 | Citigroup | Neutral |
| 2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-04 | 재개 | Guggenheim | Buy |
| 2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 재확인 | Citigroup | Buy |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-04-09 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 재확인 | Stifel | Buy |
| 2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
J.P. Morgan Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN) - Yahoo Finance
BioMarin (BMRN): Valuation Insights After Revenue Upside and PALYNZIQ Expansion News - Yahoo Finance
What analysts say about BioMarin Pharmaceutical Inc stockStock Buyback Announcements & Secret Picks Wall Street Isn’t Talking About - earlytimes.in
Sanford C. Bernstein Cuts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $88.00 - MarketBeat
Using AI based signals to follow BioMarin Pharmaceutical Inc.July 2025 Levels & Reliable Breakout Forecasts - newser.com
Key resistance and support levels for BioMarin Pharmaceutical Inc.M&A Rumor & Real-Time Volume Trigger Notifications - newser.com
Exit strategy if you’re trapped in BioMarin Pharmaceutical Inc.Trend Reversal & Verified Technical Signals - newser.com
10 Stocks to Buy With Over 50% Upside Potential - Insider Monkey
BioMarin Pharmaceutical Unleashes VOXZOGO Expansion—Is a Market Breakout Coming? - Smartkarma
Pulmonary Emphysema Market Set to Expand by 2034 with Rising COPD Prevalence and Therapeutic Innovation | DelveInsight - GlobeNewswire Inc.
Will BioMarin Pharmaceutical Inc. (BM8) stock hit analyst forecastsQuarterly Earnings Report & Long-Term Capital Growth Strategies - newser.com
Bernstein lowers BioMarin stock price target to $88 on growth concerns - Investing.com
BioMarin Pharmaceutical Inc. $BMRN Position Increased by Plato Investment Management Ltd - MarketBeat
How to read the order book for BioMarin Pharmaceutical Inc.July 2025 Action & Target Return Focused Picks - newser.com
Eleva Capital SAS Invests $1.29 Million in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Is BioMarin Pharmaceutical Inc. (BM8) stock cheap by valuation metricsDollar Strength & Weekly Stock Performance Updates - newser.com
Keybank National Association OH Sells 19,707 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
The 5 Most Interesting Analyst Questions From BioMarin Pharmaceutical’s Q3 Earnings Call - TradingView
Can BioMarin Pharmaceutical Inc. stock hit analyst price targets2025 Buyback Activity & Consistent Profit Alerts - newser.com
How to manage a losing position in BioMarin Pharmaceutical Inc.Day Trade & Fast Momentum Entry Tips - newser.com
How strong is BioMarin Pharmaceutical Inc. stock balance sheetMarket Growth Summary & Free Fast Gain Swing Trade Alerts - newser.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
What is William Blair's Estimate for BMRN Q4 Earnings? - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Purchases 14,700 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Can BioMarin Pharmaceutical Inc. (BM8) stock reach $200 price targetOptions Play & Weekly Return Optimization Plans - newser.com
Why BioMarin Pharmaceutical Inc. stock is in analyst buy zoneWeekly Trend Report & Safe Capital Growth Stock Tips - newser.com
Why BioMarin Pharmaceutical Inc. stock is seen as undervaluedJobs Report & Free Technical Pattern Based Buy Signals - newser.com
Morgan Stanley Maintains Buy on BioMarin Pharmaceutical (BMRN) - MSN
BioMarin Pharmaceutical (BMRN): Evaluating Valuation as Shares Recover 3% After Prolonged Downtrend - Sahm
How to monitor BioMarin Pharmaceutical Inc. with trend dashboards2025 Valuation Update & High Yield Stock Recommendations - newser.com
10 Best Beaten Down Growth Stocks to Buy According to Analysts - Insider Monkey
BioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 12-Month LowWhat's Next? - MarketBeat
Cantor Fitzgerald Has Negative View of BMRN FY2025 Earnings - MarketBeat
How currency fluctuations impact BioMarin Pharmaceutical Inc. stock2025 Technical Overview & Safe Swing Trade Setups - newser.com
Sentiment analysis tools applied to BioMarin Pharmaceutical Inc.Global Markets & AI Enhanced Trading Alerts - newser.com
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.71%
0.18%
자본화:
|
볼륨(24시간):